Dihexa

Dihexa is a synthetic peptide developed by researchers at Washington State University who were looking for a better way to treat Alzheimer's disease and age-related cognitive decline. It was designed to work differently from most brain-focused compounds — instead of simply boosting neurotransmitter levels or protecting existing neurons, it actually encourages the brain to grow new connections between nerve cells, a process called synaptogenesis.

The way it does this is by mimicking and amplifying the activity of a naturally occurring growth factor called HGF (hepatocyte growth factor), specifically at a receptor called c-Met. When c-Met gets activated, it triggers the kind of structural rewiring in the brain that underlies learning and long-term memory. In laboratory assays, Dihexa was found to be millions of times more potent than BDNF — one of the brain's own key growth factors — at driving this process. That comparison comes from cell models rather than human trials, but it gives a sense of how powerful the mechanism appears to be.

There is no human clinical trial data for Dihexa itself. Everything known about its effects on cognition comes from animal studies, mostly in rodents with artificially induced cognitive impairment. That said, the underlying mechanism has enough credibility that a modified version of Dihexa, called fosgonimeton, is now in active Phase 2 clinical trials for Alzheimer's and Parkinson's disease — which lends legitimacy to the core biology even if the human picture for Dihexa specifically remains incomplete.

The most significant concern with Dihexa is theoretical but important: c-Met is a known oncogene, meaning the same receptor that Dihexa activates to grow brain connections is also implicated in the growth of several cancers. No one has documented a case of Dihexa causing cancer in animal safety studies, but the concern means that anyone with a personal or family history of cancer should take it particularly seriously before considering any use.